Stifel's Recommendation
Stifel has identified DexCom (NASDAQ:DXCM) as its leading investment idea in the medical technology and supplies sector, emphasizing the company's strong second‑quarter 2026 performance and an upgraded outlook.
Financial Performance Q2 2026
DexCom reported second‑quarter 2026 revenue of $1.308 billion, representing a 12 % year‑over‑year organic increase and surpassing consensus estimates. All key metrics—revenue, gross margin, operating margin, and earnings per share—exceeded expectations.
Guidance and Estimates
Stifel raised its 2026‑2028 earnings estimates for DexCom, increased its guidance for organic revenue growth and margins, and set a new price target of $95 per share.
Growth Catalysts
- The firm highlighted the Type 2 non‑insulin‑treated diabetes market opportunity, which remains on track for year‑end 2026 coverage expected by mid‑2027.
- DexCom’s 15‑Day product is expected to drive revenue growth, with U.S. margin benefits projected in 2026 and 2027 and international contributions in 2027‑2028.
- The upcoming G8 product launch is slated for 2028 and beyond, forming part of a multi‑year roadmap for gross‑margin expansion.
Analyst Consensus
Following DexCom’s results, other analysts including RBC Capital, BTIG, and Truist Securities raised their price targets for the company.